



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER  
INFORMATION DISCLOSURE STATEMENT**

Applicant : Hatake, et al.  
App. No : 10/564,302  
Filed : January 10, 2006  
For : DRUG FOR CANCER THERAPY  
Examiner : Unknown  
Art Unit : Unknown

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 6, 2006

(Date)

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing 8 references for consideration. Eight references are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404



## INFORMATION DISCLOSURE STATEMENT

Applicant : Hatake, et al.  
App. No : 10/564,302  
Filed : January 10, 2006  
For : DRUG FOR CANCER THERAPY  
Examiner : Unknown  
Art Unit : Unknown

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 8 references to be considered by the Examiner. These 8 references are enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 6, 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/564,302
Filing Date	January 10, 2006
First Named Inventor	Hatake, et al.
Art Unit	Unknown
Examiner	Unknown
Attorney Docket No.	TOYA108.010APC

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		JP 2818056 B	08/21/98	Morinaga Milk Ind Co Ltd		Abstract
		JP S63-051337	03/04/88	Snow Brand Milk Prod Co Ltd		Abstract

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Ogura M., Saishin Igaku, Vol. 58, No. 12, pp. 102-121, 2003.	Partial
		Current Immunology Illustrated, S. Koyasu, editor, pp. 41-43, 2003.	Partial
		Hatake K., Hematology Frontier, Vol. 12, No. 11, pp. 65-71, 2002.	Partial
		Smith, "Rituximab (monoclonal anti-CD20 antibody): Mechanisms of Action and Resistance," Oncogene, Vol. 22, pp. 7359-7368, 2003.	
		Berglund, et al. "A Rapid Analytical Technique for Flow Cytometric Analysis of Cell Viability Using Calcofluor White M2R," Cytometry, Vol. 8, No. 4, pp. 421-426, 1987.	
		Molecular Medicine, Vol. 40, No. 10, pp. 1176-1181, 2003.	Partial

2655992  
060606

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.